EBAG9 _ RCAS1
- Known as:
- EBAG9 _ RCAS1
- Catalog number:
- Y213559
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- EBAG9 _ RCAS1
Related genes to: EBAG9 _ RCAS1
- Gene:
- EBAG9 NIH gene
- Name:
- estrogen receptor binding site associated antigen 9
- Previous symbol:
- -
- Synonyms:
- EB9, RCAS1
- Chromosome:
- 8q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-03-30
- Date modifiied:
- 2019-01-21
Related products to: EBAG9 _ RCAS1
Anti- EBAG9 RCAS1 Antibodyanti-EBAG9 (4A10)anti-EBAG9 (4A10)anti-EBAG9 (C-Terminus)anti-EBAG9 (C-Terminus)Anti-EBAG9 Antibodyanti-Ebag9, Goat polyclonal to Ebag9, Isotype IgG, Host GoatAnti-RCAS1 Antibody (OAAI00598)Antibodies: EBAG9 _ RCAS1 HOST: Goat Clonality: pAbCLIA Cancer-associated surface antigen RCAS1,Canis familiaris,Canis lupus familiaris,Dog,EBAG9,Estrogen receptor-binding fragment-associated gene 9 protein,RCAS1,Receptor-binding cancer antigen expresCLIA Cancer-associated surface antigen RCAS1,EBAG9,Estrogen receptor-binding fragment-associated gene 9 protein,Homo sapiens,Human,RCAS1,Receptor-binding cancer antigen expressed on SiSo cellsCLIA Cancer-associated surface antigen RCAS1,Ebag9,Estrogen receptor-binding fragment-associated gene 9 protein,Mouse,Mus musculus,Rcas1,Receptor-binding cancer antigen expressed on SiSo cellsCLIA Ebag9,Estrogen receptor-binding fragment-associated gene 9 protein,Rat,Rattus norvegicus,Receptor-binding cancer antigen expressed on SiSo cellsDog estrogen receptor binding site associated, antigen, 9 (EBAG9) ELISA kit, Species Dog, Sample Type serum, plasmaDog Receptor-binding cancer antigen expressed on SiSo cells(EBAG9) ELISA kit Related articles to: EBAG9 _ RCAS1
- To identify plasma proteins associated with glaucoma and assess the translational potential of key proteins as both biomarkers and therapeutic targets. - Source: PubMed
Xu JianmingGao YuelanYu JunXu ZiheZhang YuzhouPang Chi PuiTham Clement CYam Jason CChen Li Jia - Sequestosome 1 (p62/SQSTM1) is a multifunctional adaptor protein whose dysregulation promotes tumorigenesis through autophagy, metabolic reprogramming, and immune modulation. However, its role across cancer types and impact on the tumor immune microenvironment remain poorly defined. Here, we performed a comprehensive pan-cancer analysis to delineate the molecular and immunological landscape of p62 across human malignancies. TCGA analysis revealed rare mutations and limited prognostic impact of genomic alterations but marked transcriptomic upregulation in LIHC, LUAD, BRCA, KIRP, KICH, KIRC, and READ, correlating with poor survival, advanced stage, and higher T classification, particularly in BRCA and LUAD. Pathway analysis showed strong positive associations between p62 and metabolic adaptation and stress tolerance pathways, including oxidative phosphorylation, reactive oxygen species, and DNA repair, in most cancers. Notably, high p62 expression inversely correlated with immune cell infiltration in most epithelial cancers, such as BRCA, COAD, ESCA, HNSC, KIRC, LIHC, LUAD, LUSC, PAAD, PRAD, READ, THCA, while coinciding with elevated expression of immunosuppressive checkpoints such as PD-L1, B7-H3, EBAG9, PVR, and TGFB1, supporting a link between p62-driven metabolic remodeling and an immune-excluded tumor microenvironment. In contrast, GBM, LGG, OV, SARC, and TGCT showed positive correlations between p62 and immunoscore, with enrichment of interferon and pro-inflammatory pathways, reflecting a distinct immune-activated phenotype. Collectively, these findings identify p62 as a central regulator of tumor metabolism and immunity, suggesting that its context-dependent activity may dictate the balance between immune suppression and activation across cancers, and highlight two natural-product-derived PB1 inhibitors (ZINC70669789 and ZINC08877690) as promising candidates for therapeutic development. - Source: PubMed
Publication date: 2025/11/25
Nayeri ZahraTavakol ElaheRahmati MarvehCordani MarcoDjavaheri-Mergny MojganShariati VahidMoosavi Mohammad Amin - TNBC demonstrates poor prognosis compared to other breast cancer types due to the lack of targetable molecular markers. Protein expression of EBAG9 has been associated with unfavorable prognosis in patients with various malignancies. Recently, we identified TM9SF1 protein as a binding partner for EBAG9 protein. However, the clinical relevance of TM9SF1 and EBAG9 in TNBC remains unclear. - Source: PubMed
Publication date: 2025/09/17
Kinowaki KeiichiTakeiwa ToshihikoIkeda KazuhiroFujimoto AkihiroAzuma KotaroHorie KunikoKawabata HidetakaInoue Satoshi - Wilms tumor (WT) is the most common pediatric kidney cancer, with survival rates exceeding 90% in localized cases. However, advanced or recurrent WT remains difficult to treat due to poor prognosis and limited knowledge of its molecular mechanisms. Gene expression profiling has shown promise in identifying prognostic markers and therapeutic targets. This study aimed to identify key prognostic genes and pathways in WT, construct risk prediction models, and validate their role in tumor progression. - Source: PubMed
Publication date: 2024/11/26
Zeng QiangTao JunfengQin LiluZeng YongLiu ZhongXu MingxianZeng Linshan - Genome-wide association studies (GWASs) may help inform treatments for infertility, whose causes remain unknown in many cases. Here we present GWAS meta-analyses across six cohorts for male and female infertility in up to 41,200 cases and 687,005 controls. We identified 21 genetic risk loci for infertility (≤5E-08), of which 12 have not been reported for any reproductive condition. We found positive genetic correlations between endometriosis and all-cause female infertility ( =0.585, =8.98E-14), and between polycystic ovary syndrome and anovulatory infertility ( =0.403, =2.16E-03). The evolutionary persistence of female infertility-risk alleles in may be explained by recent directional selection. We additionally identified up to 269 genetic loci associated with follicle-stimulating hormone (FSH), luteinising hormone, oestradiol, and testosterone through sex-specific GWAS meta-analyses (N=6,095-246,862). While hormone-associated variants near and colocalised with signals for anovulatory infertility, we found no between female infertility and reproductive hormones (>0.05). Exome sequencing analyses in the UK Biobank (N=197,340) revealed that women carrying testosterone-lowering rare variants in were at higher risk of infertility (OR=2.63, =1.25E-03). Taken together, our results suggest that while individual genes associated with hormone regulation may be relevant for fertility, there is limited genetic evidence for correlation between reproductive hormones and infertility at the population level. We provide the first comprehensive view of the genetic architecture of infertility across multiple diagnostic criteria in men and women, and characterise its relationship to other health conditions. - Source: PubMed
Publication date: 2024/03/20
Venkatesh Samvida SWittemans Laura B LPalmer Duncan SBaya Nikolas AFerreira TeresaHill BarneyLassen Frederik HeymannParker Melody JReibe SaskiaElhakeem AhmedBanasik KarinaBruun Mie TErikstrup ChristianJensen Bitten AJuul AndersMikkelsen ChristinaNielsen Henriette SOstrowski Sisse RPedersen Ole BRohde Palle DSorensen ErikUllum HenrikWestergaard DavidHaraldsson AsgeirHolm HilmaJonsdottir IngileifOlafsson IsleifurSteingrimsdottir ThoraSteinthorsdottir ValgerdurThorleifsson GudmarFigueredo JessicaKarjalainen Minna KPasanen AnuJacobs Benjamin MHubers Nikki Lippincott MargaretFraser AbigailLawlor Deborah ATimpson Nicholas JNyegaard MetteStefansson KariMagi ReedikLaivuori Hannelevan Heel David ABoomsma Dorret IBalasubramanian RavikumarSeminara Stephanie BChan Yee-MingLaisk TriinLindgren Cecilia M